Artificial Organ Market By Organ Type (Artificial Heart [Prosthetic Heart Valves, Ventricular Assist Devices, and Cardiac Pacemakers], Artificial Kidney, Artificial Pancreas, Artificial Lungs, Cochlear Implants, and Other Organ Types), and By Region - Trends, Analysis and Forecast till 2034

Artificial Organ was valued at USD 29.7 Billion in 2024 and is projected to grow at a CAGR of 7.10% to reach USD 55.5 Billion by 2034.

An artificial organ is a medical device that is implanted or integrated into the body to replicate or augment the natural function of the organ. Artificial organs include implantable devices, such as fully artificial hearts and pacemakers, along with organ support machines, such as dialysis and extracorporeal membrane oxygenation (ECMO) machines. Artificial organ could be whole or a part of organ and it designs in way that it should be biocompatible and do not elicit any inflammation to surrounding organ and tissues.   

                      For More Report Details, Download Free Sample PDF

The ability of artificial organs to retain normal functioning of human organs, either temporarily or permanently, will continue to be the strongest factor driving the demand for the global artificial organs market across the globe. Increasing prevalence of chronic disorders that affect one or multiple vital organs is expected to be another demand for artificial organs. Technological advancements and rising acceptance of organ transplant technology worldwide, will collectively boost the global market growth further. Moreover, increasing awareness among population will mark remarkable growth over forecast period. However, certain prosthetic devices, including brain pacemaker, can hardly be repaired or restored by artificial organs.

Unaffordable costs of artificial organs and the entire organ implant procedure may remain longstanding restraints to rapid market growth. Several developing regions are still facing a challenge due to uncertain reimbursement policies, which is expected to restrict the market penetration in near future. Moreover, relatively lower awareness about artificial organs and organ transplant, in addition to limited knowledge about the associated surgical procedures will also impede the growth of artificial organs market. Furthermore, maintaining efficiency and quality of artificial organs in the long run is major challenge for the existing medical sector. This will continue to deter the market growth over the next few years as well.

The artificial organ market is segmented based on product, organ type, usability, application, and region.

Based on organ type, the global artificial organ is segmented into artificial heart, artificial kidney, artificial pancreas, artificial lungs, cochlear implants, and other organ types. Artificial kidney is expected to hold its highest market share in the organ type. More than 650,000 patients, per year, in the United States and an estimated 2 million patients worldwide are affected by end-stage renal disease (ESRD). Artificial heart is further is sub segmented into prosthetic heart valves, ventricular assist devices, and cardiac pacemakers.

Based on the region the global artificial organ market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America currently dominates the market for artificial organs, and is expected to continue its stronghold for a few more years. According to the recent report of the Organization for Economic Co-operation and Development (OECD), 2018, about 18% of the GDP is spent on healthcare. Out of this, a substantial part goes into transplants being performed in the United States. Therefore, the United States holds the largest share in the artificial organ market in the North American region.

Artificial Organ Market, By Organ Type:

• Artificial Heart
  • Prosthetic Heart Valves
  • Ventricular Assist Devices
  • Cardiac Pacemakers
• Artificial Kidney
• Artificial Pancreas
• Artificial Lungs
• Cochlear Implants
• Other Organ types

Artificial Organ Market, By Region:

• North America
  • Middle East & Africa
    • Middle East & Africa Farm Animal Healthcare Market, By Product
    • Middle East & Africa Farm Animal Healthcare Market, By Animal Type  
    • Middle East & Africa Farm Animal Healthcare Market, By Country
      • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • Latin America Farm Animal Healthcare Market, By Product
    • Latin America Farm Animal Healthcare Market, By Animal Type  
    • Latin America Farm Animal Healthcare Market, By Country
      • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • Asia Pacific Farm Animal Healthcare Market, By Product
    • Asia Pacific Farm Animal Healthcare Market, By Animal Type  
    • Asia Pacific Farm Animal Healthcare Market, By Country
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • Europe Farm Animal Healthcare Market, By Product
    • Europe Farm Animal Healthcare Market, By Animal Type  
    • Europe Farm Animal Healthcare Market, By Country
      • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • North America Farm Animal Healthcare Market, By Product
  • North America Farm Animal Healthcare Market, By Animal Type  
  • North America Farm Animal Healthcare Market, By Country
    • U.S.
    • Canada

The key players operating the global artificial organ market involves B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corporation, Getinge AB, Medtronic PLC, Thoratec Corporation, Biomet, Inc., Berlin Heart GmbH, ABIOMED, Inc., and HeartWare, Inc... Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the products to gain a competitive edge in the target market. For instance, in January 2020, Medtronic Receives CE Mark for Cobalt™ and Crome™ Portfolio of BlueSync™-Enabled Implantable Defibrillators, Cardiac Resynchronization Therapy-Defibrillators. ICDs monitor heart rhythms and deliver therapy to correct heart rates that are too fast and can lead to sudden cardiac arrest.

• Baxter International Inc
• B. Braun Melsungen AG
• Boston Scientific Corporation
• Getinge AB
• Medtronic PLC
• Thoratec corporation
• Biomet, Inc.
• Berlin Heart GmbH
• ABIOMED, Inc.
• HeartWare, Inc.